Trastuzumab and cardiovascular disease risk – Video abstract [69641]

Risk Factors for Trastuzumab CardiotoxicityПодробнее

Beyond anthracyclines and trastuzumab: cardiotoxicity of novel agentsПодробнее

Long-Term Risk of Heart Failure with TrastuzumabПодробнее

GASTHER2: trastuzumab for advanced gastric cancerПодробнее

Reducing Risk in Residual Breast CancerПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

#Trastuzumab in #shorts: brands, causes, mechanism of actions, contraindicationsПодробнее

Breast cancer and heart diseaseПодробнее

BREAST CANCER DRUGS AND HEART PROBLEMSПодробнее

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 yearПодробнее

Alberto Montero Discusses PERTAIN Study in HER2-Positive Breast CancerПодробнее

Treatment strategies for HER2+ metastatic breast cancerПодробнее

Introduction of the biosimilar trastuzumab and its impact on patients and servicesПодробнее

SAFE: cardiotoxicity prevention in breast cancer treated with anthracyclines and/or trastuzumabПодробнее

Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast CancerПодробнее

HER2CLIMB-04: tucatinib + trastuzumab deruxtecan in HER2+ breast cancerПодробнее

HerceptinПодробнее

TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancerПодробнее

Trastuzumab deruxtecan in metastatic HER2+ breast cancerПодробнее